KBS - Pharmaceutical Consultancy and Life Sciences - Market Insight

WHAT TYPES OF BUSINESSES ARE STRATEGIC ACQUIRERS PURSUING?

Strategic acquirers in the UK pharma consultancy and life sciences industry often target various types of businesses to bolster their operations and market position. Here are some common categories:

+ CONTRACT RESEARCH ORGANIZATIONS (CROS)

+ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS): Companies that offer comprehensive services from drug development through manufacturing. These acquisitions help acquirers enhance their production capabilities and streamline supply chains. + MEDICAL TECHNOLOGY COMPANIES Businesses that develop medical devices, diagnostics and health technologies. These acquisitions help acquirers enhance their product portfolios and create integrated healthcare solutions.

Businesses that provide outsourced research services for the pharmaceutical, biotech-nology and medical device industries. Acquiring CROs allows acquirers to expand their research capabilities and service offerings. + BIOTECH FIRMS Innovative companies focused on developing new therapies and technologies. Acquiring biotech firms allows acquirers to gain access to cutting-edge research, intellectual property and new market opportunities. + SPECIALITY PHARMACEUTICAL COMPANIES Firms that develop, and market, niche or specialised pharmaceutical products. Acquisitions in this category enable the buyer to diversify their product lines and enter new therapeutic areas. Strategic acquirers pursue these types of businesses to foster innovation, improve operational efficiency and maintain a competitive edge in the dynamic life sciences industry. Companies that provide expertise in regulatory affairs and compliance. These acquisitions help acquirers navigate complex regulatory landscapes and ensure adherence to industry standards. + REGULATORY AND COMPLIANCE CONSULTING FIRMS

+ DIGITAL HEALTH COMPANIES

Businesses that focus on digital health solutions, such as health IT, wearables and tele-medicine platforms. Acquiring these companies can enhance acquirers’ technological capabilities and improve patient outcomes.

These strategic interests drive trade acquirers and consolidators to actively participate in mergers and

acquisitions within the UK pharma consultancy and life sciences sectors, aiming for growth, innovation and improved operational efficiency.